Diagnostic Imaging and Molecular Devices Review and Outlook 2011

The diagnostic imaging and monitoring devices arena is being impacted by increasing health-care costs, an aging population, and improving technology and innovation. This shift is leading to more demand for diagnosis and treatment outside of the hospital, specially in remote areas. Innovative companies are concentrating on combining existing technologies and developing more compact, quicker and higher-quality products than current options.

Additional Information

This special report focuses on the market leaders for diagnostic imaging and monitoring devices as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of diagnostic imaging and monitoring devices prescription-drug developers and marketers is included.

Additionally provided in this report is a listing of diagnostic imaging and monitoring devices medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the diagnostic imaging and monitoring devices field.